Literature DB >> 12176561

Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients.

K Budde1, K-P Braun, P Glander, T Böhler, P Hambach, L Fritsche, J Waiser, I Mai, H-H Neumayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12176561     DOI： 10.1016/s0041-1345(02)03052-x

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

Review 1.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

2.  Inosine monophosphate dehydrogenase expression and activity are significantly lower in kidney transplant recipients with diabetes mellitus.

Authors:  Miroslav Dostalek; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Ther Drug Monit       Date:  2013-06       Impact factor: 3.681

3.  Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation.

Authors:  Nassim Kamar; Petra Glander; Jochen Nolting; Torsten Böhler; Pia Hambach; Lutz Liefeldt; Lionel Rostaing; Hans-Hellmut Neumayer; Klemens Budde
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-01       Impact factor: 8.237

4.  Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease.

Authors:  Rachel B Jones; Michael Walsh; Afzal N Chaudhry; Kenneth G C Smith; David R W Jayne
Journal:  Clin Kidney J       Date:  2014-09-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.